Dow Jones

38 686,32

1,51%

DAX

Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

HBY

Hybridon (HBY)

Hybridon

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:AMEX:HBY

1 2 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
12/09/2005	15h12	PR Newswire (US)	Hybridon Changes Name to Idera Pharmaceuticals	AMEX:HBY	Hybridon
08/09/2005	16h33	PR Newswire (US)	Hybridon, Inc. to Present at ThinkEquity Growth Conference	AMEX:HBY	Hybridon
21/06/2005	15h00	PR Newswire (US)	Hybridon, Inc., to Participate in Innate Immunity Panel at the BIO 2005 Annual International Convention	AMEX:HBY	Hybridon
17/06/2005	16h05	PR Newswire (US)	Hybridon Announces the Appointment of Robert W. Karr, M.D. to its Board of Directors	AMEX:HBY	Hybridon
01/06/2005	08h00	PR Newswire (US)	Hybridon Announces Collaboration to Develop Immune Modulatory (IMO) Compounds for Asthma and Allergy	AMEX:HBY	Hybridon
20/05/2005	20h20	PR Newswire (US)	Hybridon Announces $5 Million Private Financing	AMEX:HBY	Hybridon
16/05/2005	15h55	PR Newswire (US)	Hybridon Presents Preclinical Data on Interferon-Alpha Induction by Toll-Like Receptor 9 Agonists	AMEX:HBY	Hybridon
16/05/2005	15h35	PR Newswire (US)	Hybridon Announces Oral Presentation of Results for Phase I Trial of IMOxine(R) at ASCO 2005	AMEX:HBY	Hybridon
11/05/2005	16h05	PR Newswire (US)	Hybridon Publishes Data on Novel Synthetic Agonists of Toll-Like Receptor 9	AMEX:HBY
03/05/2005	16h05	PR Newswire (US)	Hybridon, Inc. to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference	AMEX:HBY	Hybridon
18/04/2005	16h05	PR Newswire (US)	Hybridon Presents New Preclinical Antitumor Data at AACR Supporting its IMOxine Development Program	AMEX:HBY	Hybridon
28/03/2005	17h05	PR Newswire (US)	Hybridon Reports 2004 Financial Results	AMEX:HBY	Hybridon
03/03/2005	14h00	PR Newswire (US)	Hybridon's Toll-like Receptor 9 Agonist Enhances Antitumor Activity of Cetuximab in Preclinical Studies	AMEX:HBY
22/02/2005	14h01	PR Newswire (US)	Hybridon, Inc. to Present at BIO CEO and Investor Conference	AMEX:HBY
22/11/2004	14h00	PR Newswire (US)	Hybridon Provides Updated Interim Results for the Phase 1 Trial of IMOxine(TM)	AMEX:HBY	Hybridon
15/11/2004	14h00	PR Newswire (US)	Hybridon Announces Two Presentations at the American College of Allergy, Asthma, & Immunology Annual Meeting	AMEX:HBY	Hybridon
02/11/2004	14h00	PR Newswire (US)	Hybridon to Present at Two Upcoming Conferences	AMEX:HBY	Hybridon
26/10/2004	15h00	PR Newswire (US)	Hybridon Initiates Phase 2 Trial of Its Oncology Drug Candidate, IMOxine(TM)	AMEX:HBY	Hybridon
25/10/2004	15h01	PR Newswire (US)	Hybridon to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference	AMEX:HBY	Hybridon
06/10/2004	15h01	PR Newswire (US)	Hybridon Appoints Dr. Naveen N. Anand as Vice President, Corporate and Business Development	AMEX:HBY	Hybridon
23/09/2004	17h24	PR Newswire (US)	Hybridon Appoints Alison Taunton-Rigby to Board of Directors	AMEX:HBY	Hybridon
14/09/2004	14h01	PR Newswire (US)	The Immune Response Corporation Presents New Phase II Clinical Data Indicating That REMUNE(R) Induces a HIV-Specific Immune Resp	AMEX:HBY	Hybridon
30/08/2004	16h15	PR Newswire (US)	Hybridon Announces Closing of $5.1 Million Equity Private Placement; Appointment of Sudhir Agrawal, D.Phil. as Chief Executive O	AMEX:HBY	Hybridon
04/08/2004	00h15	PR Newswire (US)	Hybridon Licenses Key VEGF Patents to Alnylam for Treatment of Ocular Diseases with RNAi Therapeutics	AMEX:HBY	Hybridon
27/07/2004	17h00	PR Newswire (US)	The Immune Response Corporation Presents Data at the International Congress of Immunology on HIV Product Candidate IR103	AMEX:HBY	Hybridon
22/07/2004	15h00	PR Newswire (US)	Hybridon's Immunomodulatory Oligonucleotides Demonstrate Mucosal Immune Responses and Adjuvant Activity Following Oral Administr	AMEX:HBY	Hybridon
15/07/2004	14h00	PR Newswire (US)	The Immune Response Corporation Presents Data Demonstrating IR103 HIV-Specific Immunologic Activity at XV International AIDS Con	AMEX:HBY	Hybridon
16/06/2004	15h00	PR Newswire (US)	Hybridon Inc. to Present at the Third Annual Needham Biotechnology Conference	AMEX:HBY	Hybridon
12/05/2004	15h00	PR Newswire (US)	Hybridon Inc. to Present at the Rodman & Renshaw Techvest Global Healthcare Conference	AMEX:HBY	Hybridon
10/05/2004	15h02	PR Newswire (US)	Hybridon's Immunomodulatory Drug Candidate, IMOxine(TM), Produces Immune Response in Patients with Refractory Advanced Solid Tum	AMEX:HBY	Hybridon